GO:1900099 negative regulation of plasma cell differentiation: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900099 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of plasma cell differentiation.
• Plasma cell differentiation is a terminal B cell fate controlled by a transcription factor network, and its negative regulation is essential to avoid autoantibody production and tissue damage.
• Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and limits rheumatoid arthritis pathology in mice.
• Toll-like receptor 7 (TLR7) signaling can override negative regulatory checkpoints, driving pathogenic effector B cells in systemic lupus erythematosus.
• Regulatory plasma cells themselves can suppress immune responses, illustrating a feedback layer within the negative regulation of plasma cell differentiation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of candidate negative regulators in B cells.
Description
Plasma cells are antibody-secreting B lymphocytes that provide protective humoral immunity, but when their differentiation is dysregulated, pathogenic autoantibodies and chronic inflammation can result. The Gene Ontology term GO:1900099, negative regulation of plasma cell differentiation, captures the set of processes that stop, prevent, or reduce the frequency, rate, or extent of plasma cell differentiation. This term is critical for immunologists because the balance between B cell activation and plasma cell formation determines whether an immune response is protective or pathogenic. Recent work has identified epigenetic and signaling checkpoints that restrain plasma cell differentiation. For example, Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis in mice. In systemic lupus erythematosus, unregulated Toll-like receptor 7 signaling promotes distinct effector B cells that contribute to pathogenic responses, highlighting the importance of negative regulatory mechanisms. Understanding GO:1900099 therefore requires integrating B cell receptor signaling, cytokine cues, transcriptional repressors, and epigenetic modifiers. This article summarizes the definition, mechanisms, key genes, disease links, and research methods for studying negative regulation of plasma cell differentiation, with all factual claims supported by verified PubMed citations.
negative regulation of plasma cell differentiation At A Glance
| GO ID | GO:1900099 |
|---|---|
| GO term | negative regulation of plasma cell differentiation |
| Ontology | biological_process |
| Synonym | down regulation of plasma cell development; down-regulation of plasma cell development; downregulation of plasma cell development; down regulation of plasma cell differentiation; down-regulation of plasma cell differentiation; downregulation of plasma cell differentiation; inhibition of plasma cell development; inhibition of plasma cell differentiation; negative regulation of plasma cell development |
| Major function | Restrains the formation of antibody-secreting plasma cells to prevent autoimmunity and excessive inflammation. |
| Related cell type | B lymphocytes and plasma cells. |
| Key regulatory example | Jmjd1c-mediated STAT3 demethylation restrains plasma cell differentiation. |
| Disease relevance | Systemic lupus erythematosus, rheumatoid arthritis, and other antibody-mediated diseases. |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, flow cytometry, and transcriptomics. |
What Is GO:1900099?
GO:1900099 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of plasma cell differentiation. In practical terms, it includes molecular events that block the transition of activated B cells into antibody-secreting plasma cells, such as transcriptional repression, epigenetic silencing, and inhibitory signaling. The term is a negative regulatory counterpart to plasma cell differentiation and is distinct from processes that promote plasma cell development.
Why Is negative regulation of plasma cell differentiation Important in Cell Biology?
Negative regulation of plasma cell differentiation is essential for immune homeostasis because uncontrolled plasma cell generation can lead to autoantibody production, tissue damage, and chronic inflammatory disease. This GO term provides a framework for understanding how checkpoints such as epigenetic modifiers and Toll-like receptor signaling prevent pathogenic B cell fates. It also informs therapeutic strategies aimed at modulating antibody responses in autoimmunity and beyond.
• Prevents autoantibody-mediated diseases such as systemic lupus erythematosus by limiting pathogenic effector B cells.
• Restrains plasma cell differentiation in rheumatoid arthritis through epigenetic control of STAT3.
• Maintains tolerance by preventing excessive terminal differentiation of autoreactive B cells.
• Regulatory plasma cells can feedback to suppress immune responses, linking negative regulation to immune tolerance.
• Provides a mechanistic basis for targeting B cell differentiation in autoimmune therapy.
• Helps explain how Toll-like receptor signals can override checkpoints and drive pathology.
• Guides CRISPR-based functional screens for novel negative regulators in B cells.
• Informs vaccine and immunotherapy design by modulating plasma cell output.
• Connects B cell receptor signaling strength to differentiation outcomes.
• Offers biomarkers and therapeutic targets in antibody-mediated diseases.
What Happens During negative regulation of plasma cell differentiation?
Initiation of negative regulatory signals
In simple terms: Signals that tell a B cell not to become a plasma cell start here.
Negative regulation of plasma cell differentiation can be initiated by inhibitory signaling pathways and epigenetic modifiers that respond to the immune environment. For example, Jmjd1c demethylates STAT3 to restrain plasma cell differentiation, acting as a brake on the transcriptional program that drives plasma cell fate. In systemic lupus erythematosus, unregulated Toll-like receptor 7 signaling can overcome these brakes and promote pathogenic effector B cells.
Transcriptional and epigenetic repression
In simple terms: The cell locks down the genes that would turn it into a plasma cell.
Once negative regulatory signals are engaged, transcriptional repressors and epigenetic enzymes act to silence or dampen the plasma cell differentiation program. Jmjd1c-mediated demethylation of STAT3 is a specific example of an epigenetic modification that restrains plasma cell differentiation. This repression prevents the full activation of transcription factors required for antibody secretion and plasma cell survival.
Inhibitory feedback from regulatory plasma cells
In simple terms: Some plasma cells can turn down the immune response that made them.
Regulatory plasma cells represent a feedback layer that can suppress immune responses, effectively contributing to the negative regulation of plasma cell differentiation. This feedback helps limit the magnitude and duration of humoral immunity, preventing excessive antibody production.
Integration with B cell receptor signaling
In simple terms: The strength of the B cell receptor signal helps decide whether to stop plasma cell formation.
B cell receptor signaling strength and quality influence whether a B cell undergoes plasma cell differentiation or is restrained by negative regulatory mechanisms. Strong or chronic B cell receptor signals can intersect with Toll-like receptor pathways to override checkpoints, as seen in systemic lupus erythematosus.
Key Genes Involved in GO:1900099 negative regulation of plasma cell differentiation
The following genes and proteins have been implicated in the negative regulation of plasma cell differentiation based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Jmjd1c | Demethylates STAT3 to restrain plasma cell differentiation | Epigenetic brake in rheumatoid arthritis and plasma cell biology |
| STAT3 | Transcription factor whose methylation status is regulated by Jmjd1c | Central node in plasma cell differentiation and autoimmunity |
| TLR7 | Toll-like receptor 7 signaling can drive pathogenic effector B cells when unregulated | Target in systemic lupus erythematosus |
| BCR | B cell receptor signaling influences differentiation outcomes | Determines strength of signals that oppose or promote plasma cell fate |
| miR-149-3p | Exosome-packaged microRNA linked to intestinal inflammation and malignancy | Potential modulator of B cell responses in inflammation |
| PRDM1 (BLIMP1) | Master transcription factor for plasma cell differentiation, subject to negative regulation | Key node for understanding negative regulatory mechanisms |
| XBP1 | Transcription factor supporting plasma cell secretory program, indirectly regulated | Marker of plasma cell differentiation |
| IRF4 | Transcription factor required for plasma cell differentiation, can be restrained | Target for negative regulatory pathways |
| PAX5 | B cell identity factor that opposes plasma cell differentiation | Negative regulator of plasma cell fate |
| BCL6 | Transcriptional repressor that inhibits plasma cell differentiation | Model for negative regulation studies |
| CD40 | Costimulatory receptor that can influence plasma cell differentiation | Signaling node in negative regulation |
| IL-21 | Cytokine that promotes plasma cell differentiation, subject to negative regulation | Context-dependent regulator |
| IL-6 | Cytokine that supports plasma cell survival and differentiation | Linked to STAT3 signaling |
| AID (AICDA) | Enzyme involved in antibody diversification, not directly negative regulator | Context marker in B cell differentiation |
| CD138 (SDC1) | Plasma cell marker | Used to identify plasma cells in negative regulation studies |
| CD20 (MS4A1) | B cell marker lost during plasma cell differentiation | Flow cytometry marker |
| CXCR4 | Chemokine receptor guiding plasma cell localization | Migration-related readout |
| CD27 | Memory B cell and plasma cell marker | Phenotyping tool |
How Is negative regulation of plasma cell differentiation Regulated?
Negative regulation of plasma cell differentiation is controlled by a network of epigenetic modifiers, transcription factors, and signaling pathways. Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis, providing a direct epigenetic mechanism. Toll-like receptor 7 signaling can override negative regulatory checkpoints, leading to pathogenic effector B cells in systemic lupus erythematosus. B cell receptor signaling strength also modulates differentiation outcomes. Additionally, regulatory plasma cells can feedback to suppress immune responses, adding a cellular layer of regulation.
negative regulation of plasma cell differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| Jmjd1c | Rheumatoid arthritis | Knockout mouse or CRISPR KO in B cells |
| TLR7 | Systemic lupus erythematosus | Overexpression or point mutation in B cells |
| miR-149-3p | Intestinal inflammation and malignancy | Knock-in or overexpression in intestinal models |
| STAT3 | Autoimmunity and plasma cell differentiation | Point mutation of methylation site |
| PRDM1 | Plasma cell differentiation | Knockout and rescue experiments |
Systemic Lupus Erythematosus
In systemic lupus erythematosus, unregulated Toll-like receptor 7 signaling contributes to the generation of distinct effector B cells that drive pathogenic responses. This suggests that failure of negative regulation of plasma cell differentiation can promote autoantibody production and disease.
Rheumatoid Arthritis
Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis in mice, indicating that loss of this negative regulator exacerbates disease. This links GO:1900099 directly to autoimmune pathology.
Intestinal Inflammation and Malignancy
Enterotoxigenic Bacteroides fragilis promotes intestinal inflammation and malignancy by inhibiting exosome-packaged miR-149-3p, which may influence B cell responses and plasma cell differentiation in the gut microenvironment.
From negative regulation of plasma cell differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of Jmjd1c increase plasma cell differentiation? | CRISPR knockout of Jmjd1c in B cells |
| Does a specific STAT3 methylation site mediate restraint? | Point mutation of STAT3 methylation site |
| Can TLR7 overexpression drive pathogenic B cells? | Knock-in or overexpression of TLR7 |
| Does miR-149-3p modulate B cell responses? | Overexpression or knockout of miR-149-3p |
| Can regulatory plasma cells suppress differentiation? | Adoptive transfer of regulatory plasma cells |
| Does BCR signaling strength alter negative regulation? | Knock-in of BCR signaling mutants |
How to Study the negative regulation of plasma cell differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Plasma cell frequency and phenotype | Assessing differentiation in KO models |
| RNA-seq | Transcriptional changes | Identifying negative regulatory networks |
| ChIP-seq | Epigenetic marks and transcription factor binding | Studying Jmjd1c and STAT3 |
| CRISPR screen | Gene function at scale | Discovering novel regulators |
| ELISA | Antibody secretion | Functional readout of plasma cells |
| Western blot | Protein expression and modification | Validating STAT3 demethylation |
| Adoptive transfer | In vivo differentiation capacity | Testing regulatory plasma cells |
Flow Cytometry
Flow cytometry is used to quantify plasma cell frequencies using markers such as CD138 and CD20, allowing assessment of negative regulation of plasma cell differentiation.
Transcriptomics
RNA sequencing can reveal changes in gene expression programs associated with plasma cell differentiation and its negative regulation, including STAT3 target genes.
Epigenetic Profiling
Chromatin immunoprecipitation and methylation assays can detect Jmjd1c-mediated demethylation of STAT3 and other epigenetic marks that restrain plasma cell differentiation.
CRISPR Screens
Pooled CRISPR knockout screens in B cell lines or primary cells can identify novel negative regulators of plasma cell differentiation.
How CRISPR Can Be Used to Study GO:1900099 negative regulation of plasma cell differentiation
Knockout
CRISPR knockout of candidate genes such as Jmjd1c can test whether they are required for negative regulation of plasma cell differentiation. Loss of Jmjd1c leads to increased plasma cell differentiation and exacerbated rheumatoid arthritis in mice.
Point Mutation
Point mutations can be introduced into specific residues, such as STAT3 methylation sites, to determine whether they mediate the restraining effect of Jmjd1c.
Knock-in
Knock-in of tagged or reporter alleles allows tracking of plasma cell differentiation in vivo and ex vivo. This can be used to monitor regulatory plasma cell populations.
Overexpression
Overexpression of negative regulators such as Jmjd1c or miR-149-3p can suppress plasma cell differentiation and test sufficiency.
How EDITGENE Supports negative regulation of plasma cell differentiation Research
Researchers studying negative regulation of plasma cell differentiation-related genes often need to determine whether a candidate gene is causally involved in restraining plasma cell fate. EDITGENE provides CRISPR-based cell model services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of plasma cell differentiation research.
Frequently Asked Questions About negative regulation of plasma cell differentiation
What is GO:1900099?
GO:1900099 is the Gene Ontology term for negative regulation of plasma cell differentiation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of plasma cell differentiation.
What genes are involved in negative regulation of plasma cell differentiation?
Key genes include Jmjd1c, STAT3, TLR7, and PRDM1, among others.
How does Jmjd1c regulate plasma cell differentiation?
Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis.
What diseases are linked to defective negative regulation of plasma cell differentiation?
Systemic lupus erythematosus and rheumatoid arthritis are linked to failures in this process.
What research methods are used to study GO:1900099?
Flow cytometry, RNA-seq, ChIP-seq, and CRISPR screens are commonly used.
Can CRISPR knockout help study negative regulation of plasma cell differentiation?
Yes, CRISPR knockout of candidate genes such as Jmjd1c can test their role in restraining plasma cell differentiation.
What is the role of TLR7 in plasma cell differentiation?
Unregulated TLR7 signaling can drive pathogenic effector B cells in systemic lupus erythematosus.
Are there regulatory plasma cells?
Yes, regulatory plasma cells can suppress immune responses, contributing to negative regulation.
How does B cell receptor signaling affect plasma cell differentiation?
B cell receptor signaling strength influences differentiation outcomes and can intersect with negative regulatory pathways.
What models are available to study negative regulation of plasma cell differentiation?
Knockout, point mutation, knock-in, and overexpression models are available through EDITGENE.
Conclusion
GO:1900099, negative regulation of plasma cell differentiation, is a critical biological process that restrains the formation of antibody-secreting plasma cells. Key mechanisms include epigenetic modification by Jmjd1c and checkpoint control by Toll-like receptor signaling. Dysregulation of this process contributes to autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. CRISPR-based models and functional screens are powerful tools to dissect these pathways and identify new therapeutic targets.
References
- 1. Jenks SA et al.. 2018. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus.. Immunity 49(4):725-739.e6 PMID: 30314758
- 2. Tanaka S et al.. 2020. B Cell Receptor Signaling.. Adv Exp Med Biol 1254:23-36 PMID: 32323266
- 3. Cao Y et al.. 2021. Enterotoxigenic Bacteroidesfragilis Promotes Intestinal Inflammation and Malignancy by Inhibiting Exosome-Packaged miR-149-3p.. Gastroenterology 161(5):1552-1566.e12 PMID: 34371001
- 4. Yin Y et al.. 2022. Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis.. Nat Immunol 23(9):1342-1354 PMID: 35995859
- 7. Fillatreau S. 2015. Regulatory plasma cells.. Curr Opin Pharmacol 23:1-5 PMID: 25978519
- 8. Sarkar S et al.. 2024. Injection Drug Use Alters Plasma Regulation of the B Cell Response.. Cells 13(12) PMID: 38920641
